Tandem Diabetes Care, Inc. (TNDM)
NASDAQ: TNDM · Real-Time Price · USD
15.30
-0.10 (-0.65%)
At close: Jun 18, 2026, 4:00 PM EDT
15.60
+0.30 (1.96%)
After-hours: Jun 18, 2026, 7:39 PM EDT
Tandem Diabetes Care Revenue
Tandem Diabetes Care had revenue of $247.22M in the quarter ending March 31, 2026, with 5.46% growth. This brings the company's revenue in the last twelve months to $1.03B, up 4.54% year-over-year. In the year 2025, Tandem Diabetes Care had annual revenue of $1.01B with 7.93% growth.
Revenue (ttm)
$1.03B
Revenue Growth
+4.54%
P/S Ratio
1.02
Revenue / Employee
$411,014
Employees
2,500
Market Cap
1.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.01B | 74.54M | 7.93% |
| Dec 31, 2024 | 940.20M | 192.49M | 25.74% |
| Dec 31, 2023 | 747.72M | -53.50M | -6.68% |
| Dec 31, 2022 | 801.22M | 98.42M | 14.00% |
| Dec 31, 2021 | 702.80M | 203.97M | 40.89% |
| Dec 31, 2020 | 498.83M | 136.53M | 37.68% |
| Dec 31, 2019 | 362.31M | 178.44M | 97.05% |
| Dec 31, 2018 | 183.87M | 76.27M | 70.88% |
| Dec 31, 2017 | 107.60M | 23.35M | 27.72% |
| Dec 31, 2016 | 84.25M | 11.40M | 15.65% |
| Dec 31, 2015 | 72.85M | 23.13M | 46.51% |
| Dec 31, 2014 | 49.72M | 20.72M | 71.41% |
| Dec 31, 2013 | 29.01M | 26.53M | 1,072.00% |
| Dec 31, 2012 | 2.48M | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AdaptHealth | 3.29B |
| QuidelOrtho | 2.66B |
| Enovis | 2.28B |
| CONMED | 1.37B |
| Inspire Medical Systems | 915.25M |
| Alphatec Holdings | 787.08M |
| Avanos Medical | 715.90M |
| Artivion | 458.69M |
TNDM News
- 11 days ago - Tandem Diabetes Care Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 14 days ago - Tandem Diabetes receives CE Mark for expanded indications of AID systems - TheFly
- 14 days ago - Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy - Business Wire
- 18 days ago - Wells upgrades Tandem Diabetes on ‘transformational’ pharmacy model - TheFly
- 19 days ago - Tandem Diabetes upgraded to Overweight from Equal Weight at Wells Fargo - TheFly
- 22 days ago - Tandem Diabetes price target lowered to $17 from $22 at Citi - TheFly
- 23 days ago - Tandem Diabetes price target lowered to $21 from $24 at Goldman Sachs - TheFly
- 4 weeks ago - Tandem Diabetes Care Transcript: AGM 2026 - Transcripts